Drawing for KINDLIA

USPTO serial 88517655

KINDLIA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
KLUWE, CHERYL D
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with KINDLIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Elsa D. Lemoine

Elsa D. Lemoine AMGEN INC.One Amgen Center Drive,Trademark Operations-MS-28-5ATHOUSAND OAKS, CA 91320-1799

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders; pharmaceutical preparations used for the treatment of renal and kidney disorders; pharmaceutical preparations for the treatment of cardiovascular diseases and disorders, inflammatory diseases and disorders, autoimmune diseases and disorders, oncological diseases and disorders, hematological diseases and disorders, tumorous diseases, autoimmune diseases, inflammation, inflammatory diseases and disorders, neurologic diseases and disorders, metabolic diseases and disorders; pharmaceuticals for stimulating the growth of platelets and platelet precursor cells; erythropoiesis stimulating protein; pharmaceuticals for stimulating white blood cell production; pharmaceuticals for modulating the level of calcium in the bloodstream and for the treatment of hyperparathyroidism and hypercalcemia; pharmaceuticals for treating human immune diseases and conditions; pharmaceutical preparations for the treatment of bone disease; and pre-filled syringes containing pharmaceutical preparations for treatment of the aforementioned diseases and disorders and complications associated therewithACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 21, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 20, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 4, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 2, 2021EX3GSOU EXTENSION 3 GRANTED—
Nov 2, 2021EXT3SOU EXTENSION 3 FILED—
Nov 2, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 6, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 6, 2021EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
May 6, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 6, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 6, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 4, 2021EX2GSOU EXTENSION 2 GRANTED—
May 4, 2021EXT2SOU EXTENSION 2 FILED—
May 4, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 3, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 30, 2020EX1GSOU EXTENSION 1 GRANTED—
Oct 30, 2020EXT1SOU EXTENSION 1 FILED—
Oct 30, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 19, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 24, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 24, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 4, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 18, 2020ALIEASSIGNED TO LIE—
Feb 10, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 6, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 5, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 5, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 3, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 3, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 3, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 26, 2019DOCKASSIGNED TO EXAMINER—
Jul 24, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 19, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance